Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry

Annals of Oncology : Official Journal of the European Society for Medical Oncology
R BartschBiotherapy Development Association (BDA)

Abstract

Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants.

References

Oct 7, 1994·Science·P A FutrealY Miki
Aug 30, 2000·Nature·C M PerouD Botstein
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HowellC Morris
Dec 24, 2003·Cancer·Sharon H GiordanoGabriel N Hortobagyi
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne BoulayHeidi A Lane
Apr 19, 2007·Journal of the National Cancer Institute·Maurizio ScaltritiJosé Baselga
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Feb 21, 2009·The New England Journal of Medicine·Christos Sotiriou, Lajos Pusztai
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert GrayRobert L Comis
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
Nov 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth A MittendorfAna M Gonzalez-Angulo
Apr 22, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maurizio ScaltritiJosé Baselga
Jul 29, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeff SperindeAllan Lipton
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMiguel Martin
Oct 19, 2010·Critical Reviews in Oncology/hematology·Anna EmdeUNKNOWN Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME)
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Belinda E KielyMartin R Stockler
Jul 16, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Xavier PivotDavid W Miles
Dec 8, 2011·Breast Cancer Research and Treatment·Aoife J LoweryKarl J Sweeney
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Jan 20, 2012·The Lancet Oncology·Michael UntchUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group

❮ Previous
Next ❯

Citations

Sep 23, 2014·Expert Opinion on Drug Safety·Omar Abdel-Rahman, Hesham ElHalawani
Sep 1, 2015·Critical Reviews in Oncology/hematology·María Teresa MartínezAna Lluch
Dec 17, 2014·BMC Cancer·Alberto Cedro-TandaNormand García-Hernández
Jul 1, 2016·Journal of Experimental & Clinical Cancer Research : CR·Alessandra FabiFrancesco Cognetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Nature Reviews. Drug Discovery
Gideon BollagPeter Hirth
Yao xue xue bao = Acta pharmaceutica Sinica
Hong-Qin Yang, Xue-Jun Li
International Journal of Clinical Practice
R ShabsighM Zitzmann
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alberto Ocaña, Atanasio Pandiella
© 2021 Meta ULC. All rights reserved